Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Pharmalot
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharma
STAT+

Asia Intel: A new style of Singapore biotech eyes ASCO

By EJ LaneMarch 3, 2017

Reprints
STAT Plus - Asia Intel
Alex Hogan/STAT

SINGAPORE — A young immuno-oncology company aims to pitch biomarker data for its lead drug candidate at the American Society of Clinical Oncology meeting in Chicago this summer, spreading the word about its ongoing Phase 3 trials.

Tessa Therapeutics could also send a message to fledgling Asian biotech hubs hoping to replicate the success of centers in other parts of the world.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

EJ Lane

Tags

FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Cerebral and other telehealth startups face new legal and…
Cerebral and other telehealth startups face new legal and regulatory challenges over ad models
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

Recommended Stories